ArticleThyroid : official journal of the American Thyroid Association2014
Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.
Article in Thyroid : official journal of the American Thyroid Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.World journal of surgical oncology · 2016Pooled it
- Independent Prognostic Value ofCancers · 2026Review
- Review
- X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival inFrontiers in endocrinology · 2022Article
- TRIM32: A Multifunctional Protein Involved in Muscle Homeostasis, Glucose Metabolism, and Tumorigenesis.Biomolecules · 2021Review
- Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2020Review
- The Role of BRAF V600E in Reducing AUS/FLUS Diagnosis in Thyroid Fine Needle Aspiration.Endocrine pathology · 2019Article
- Prognostic Value of XIAP Level in Patients with Various Cancers: A Systematic Review and Meta-Analysis.Journal of Cancer · 2019Article
- Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience.Oncology letters · 2018Article
- Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2018Article
- Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma.Scientific reports · 2017Article
- A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma.Endocrine connections · 2017Review
- Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2016Article
- Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma.British journal of cancer · 2016Article
- A closer look at papillary thyroid carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2015Review
- The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades.Endocrinology and metabolism (Seoul, Korea) · 2014Article
- Current status and future perspectives in differentiated thyroid cancer.Endocrinology and metabolism (Seoul, Korea) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe X-linked inhibitor of apoptosis protein (XIAP) is associated with carcinogenesis, cancer progression, and metastasis through inhibition of the caspase-mediated apoptotic pathway. The BRAF(V600E) mutation is the most common genetic alteration and an established prognostic marker in papillary thyroid cancer (PTC). The prevalence of the BRAF mutation is very high and is up to 80% in Korean PTC patients. In the present study, we evaluated the potential role of XIAP expression as a novel prognostic marker to predict recurrence, in combination with the BRAF(V600E) mutational status.
methodsThe study enrolled 164 patients with conventional PTC who underwent bilateral thyroidectomy followed by immediate (131)I ablation. The presence of the BRAF(V600E) mutation was evaluated by direct sequencing. The degree of XIAP expression was evaluated by immunohistochemical (IHC) staining using a monoclonal antibody.
resultsThe BRAF(V600E) mutation was found in 123 of 164 patients (75%) with classical PTC. XIAP expression was positive in 128 of 164 patients (75%), and positive XIAP expression was significantly associated with the presence of lateral cervical lymph node metastases (p=0.01). XIAP expression was more frequent in BRAF(V600E) mutated PTCs than in BRAF wild type PTCs (p=0.048). The BRAF(V600E) mutation was significantly associated with cancer recurrence in study subjects (hazard ratio=2.98, p=0.039). PTCs positive for the BRAF(V600E) mutation but negative for XIAP expression had a significantly higher rate of recurrent PTC (hazard ratio=4.53, p=0.012).
conclusionThe evaluation of XIAP expression and BRAF mutational analysis was more useful for the prediction of cancer recurrence in patients with PTC than BRAF genotype alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.